Use of extracorporeal liver assist device and auxiliary liver transplantation in fulminant hepatic failure.
The case history of a 14-year-old boy with fulminant hepatic failure secondary to non-A, non-B hepatitis who fulfilled selection criteria for orthotopic liver transplantation is described. Two forms of liver support were used (extracorporeal liver assist device and an auxiliary partial orthotopic liver transplantation) to provide additional time to allow spontaneous recovery to occur. During the 66 h of extracorporeal haemoperfusion through the device, haemodynamic stability was maintained along with improvements in serum bilirubin (555 to 381 mumol/l), and international normalized ratio (INR) (3.7 to 2.9). Deterioration in these parameters was observed following cessation of treatment and 10 h later, after a donor liver had become available, an auxiliary transplant was performed. Clinical recovery, though initially slow, was eventually complete, with histopathological and scintigraphic evidence of full liver regeneration at 3 months. Withdrawal of his immunosuppressive drugs began at 6 months and was complete by 14 months after auxiliary transplantation. He has since remained well with normal liver function tests. Temporary liver support may provide additional time for spontaneous recovery of the native liver to occur in selected cases of fulminant hepatic failure, even when criteria are fulfilled for orthotopic liver grafting.
McCarthy
M
M
Institute of Liver Studies, King's College Hospital, London, UK.
Ellis
A J
AJ
Wendon
J A
JA
Heaton
N
N
Rela
M
M
Buxton-Thomas
M
M
Hughes
R D
RD
Portmann
B C
BC
Williams
R
R
D000293:Adolescent; D006084:Graft Rejection / Q000517:prevention & control; D006464:Hemoperfusion / Q000379:methods*; D016751:Hepatitis E / Q000150:complications / Q000175:diagnosis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017114:Liver Failure, Acute / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D012074:Remission Induction
D007166:Immunosuppressive Agents